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Aims The aim of the present study was to analyze gender
disparities in a large cohort of acute coronary syndrome
(ACS) patients from the Zurich Acute Coronary Syndrome
(Z-ACS) Registry.
Methods Gender disparities in ACS were examined. The
primary endpoint included in-hospital death rate, and the
secondary endpoint major adverse cardiac and
cerebrovascular events (MACCEs) at 30-day follow-up.
Furthermore, independent predictors for MACCEs and
death were identified.
Results In total, 2612 patients with ACSwere identified. Out
of these, 23% were women. The mean age was higher in
women (68.6W12.2; P<0.001). Troponin-T on admission
(1.33W4.64 vs. 1.19W3.04mg/l; PU0.002) and N-terminal
of the prohormone brain natriuretic peptide on admission
(3456.2W7286.7 vs. 1665.6W4800.6 ng/l; P<0.001) were
higher in women compared with men. Single-vessel
disease was more common in women (44.9 vs. 39.7%;
PU0.023) and, conversely, multivessel disease was more
prevalent in male patients as compared with their female
counterparts (59.4 vs. 54.4%; PU0.029). At discharge, men
were more likely prescribed statins (89.4 vs. 85.2%;
PU0.004). Overall mortality and MACCEs were similar for
both genders. In women, peak creatine kinase and peak
C-reactive protein emerged as independent predictors for
MACCEs and SBP on admission, and maximal C-reactive
protein and use of glycoprotein IIb/IIIa inhibitors
(GPIIb/IIIa) as strong independent predictors for in-hospital
death.
Conclusion The present results suggest a closing gap in
short-term outcome and improvement in cardiac care
between women and men. Nonetheless, differences in
treatment strategies continue to exist, particularly
pertaining to statin regimens at discharge, which might
potentially have a powerful impact on long-term outcomes
and gender disparities.
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Introduction
In the realm of cardiovascular disease (CVD),women have
been historically understudied, despite the fact that they
are equally adversely affected as men. As such, the WHO
estimates that women suffer about 3.3 million deaths
annually due to myocardial infarction.1 This is an aston-
ishing finding, which has been on the rise, exceeding the
number of deaths in men from CVD since 1984.1 More-
over, there is an accumulating body of evidence that not
onlywomen are understudied in clinical trials; they are also
underdiagnosed due to different symptoms upon presen-
tation, and even under-treated on admission.2–7 Under-
representation of women was particularly stressed in the
American Heart Association (AHA) prevention guidelines
of CVD in women published in 2007.8 These guidelines
were based on a mere population of 30% women enrolled
in the clinical trials, albeit they exhibit a similar prevalence
of coronary artery disease (CAD) as men.2 Likewise,
women’s enrollment in randomized clinical trials (RCTs)
in European countries9,10 remains minuscule overall, ran-
ging between 16 and 25%.10,11
Recent findings from the INTERHEART Study12
demonstrated that gender-related differences in cardio-
vascular risk factors included diabetes and hypertension
as strong risk factors, specifically in women. Thus, there is
an urgent need for international improvement in clinical
trial enrollment, guidelines establishment and healthcare
delivery in women as a vulnerable population. The
current study therefore aimed to investigate gender-
related differences in the clinical profile and treatment,
as well as in-hospital outcomes in acute coronary syn-
drome (ACS) in a large cohort of patients.
Methods
Data collection
We included consecutive patients with the diagnosis of
ACS at the University Hospital of Zurich, Switzerland
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(USZ) from 2007 to 2012 who underwent coronary angio-
graphy. All patients enrolled in this registry were at least
18 years of age. ACS was classified as ST-segment myo-
cardial infarction (STEMI), non-ST-segment myocardial
infarction (NSTEMI) or unstable angina (UA) based on
the classification by Thygesen et al.13 Patient data were
collected from the an in-hospital clinical electronic
patient record system at the USZ. Data were analyzed
regarding baseline characteristics, laboratory values,
patients’ cardiovascular medications on admission and
discharge. CAD was defined as single-vessel disease
(SVD) or multivessel disease (MVD), and the culprit
lesion was categorized as left main artery, left anterior
descending (LAD) artery, circumflex artery, right coron-
ary artery or coronary artery bypass graft (CABG).
Furthermore, we included the hemodynamic parameters
such as blood pressure, heart rate, left ventricular end-
diastolic pressure and left ventricular ejection fraction
(LVEF) from the left ventricular angiogram if performed.
The study was performed on behalf of the Special Pro-
gramme University Medicine (SPUM) and a quality
control of patients with ACS at the USZ. The study
cohort was in part shared with the Zurich Acute Coronary
Syndrome Registry (Z-ACS) reported elsewhere.14
Short-term follow-up
In-hospital outcome was reviewed, and the primary
endpoint comprised overall in-hospital death and the
secondary endpoint included major adverse cardiac event
(MACCE), which was defined as in-hospital death, non-
fatal myocardial infarction, revascularization, CABG,
stent thrombosis, as well as stroke at 30 days of follow-
up. Myocardial infarction was defined as angina pectoris
symptoms combined with elevated cardiac enzymes and
typical ECG patterns for myocardial infarction. Stroke
was present if reviewed independently by a neurologist
and classified according to focal neurologic deficits lasting
longer than 24 h with a clinically relevant lesion on
brain scanning.
Statistical analysis
SPSS software (Version 20.0, Chicago, Illinois, USA) was
applied for all statistical analysis. A P value less than
0.05 was defined as statistically significant. Normally
distributed variables are presented as frequencies or
proportions, or as mean with SD. All baseline character-
istics, hemodynamics, medication and outcomes for the
gender analysis were summarized using frequency tables
with count and proportion for each category, or median
and interquartile range (IQR), respectively. Median and
IQR were used for non-Gaussian distribution that was
tested by Shapiro–Wilk test.
Differences between groups were tested using chi-square
or Fisher’s exact test for nominal endpoints, or the
Kruskal–Wallis tests for continuous endpoints. Survival
analysis for male and female patients at 30-day follow-up
was performed applying the Kaplan–Meier method for
the combined endpoint of MACCE. The curves were
analyzed using the log-rank sum test.
Univariate and multivariate nominal regression models
and odds ratio (OR) were applied to identify independent
predictors of in-hospital death and MACCE. Variables
included in the model were selected in a stepwise for-
ward-selection manner. Entry and retention sets with a
P value of less than 0.05 indicated a significant difference.
A variable’s risk was expressed as an ORwith correspond-
ing 95% confidence interval (CI).
Results
Baseline characteristics
The baseline characteristics after stratification into two
groups are shown in Tables 1–3. In total, 2612 patients
were included in the present study. Out of these, 2011
(77%) patients were men and 601 (23%) were women.
The average age was significantly higher in women as
compared with men (68.6 12.2 vs. 62.4 12.3 years;
P< 0.001; Table 1 and Fig. 1). A history of hypertension
was more prevalent in women than in men (62.1 vs.
54.0%; P< 0.001). In contrast, current cigarette smoking
was more common among men (44.8 vs. 31.4%;
P< 0.001). The prevalences of diabetes mellitus, hyper-
lipidemia, obesity and known family history of CVDwere
similar in both groups (Table 1).
Previous medications including aspirin, clopidogrel,
statin, beta-blocker and angiotensin-converting-enzyme
(ACE)-inhibitor were similar in both groups (Table 1).
Only diuretics, angiotensin receptor blockers (ARBs) and
calcium channel blockers (CCBs) were more often pre-
scribed among women prior to the admission (Table 1).
At discharge, men were more likely prescribed statins
(89.4 vs. 85.2%; P¼ 0.004) and ACE-inhibitor (67.0 vs.
56.8%; P< 0.001; Table 1). Conversely, women were
more likely to be treated with clopidogrel (81.3 vs.
72.4%; P< 0.001), diuretics (26.5 vs. 20.0%; P¼ 0.001)
and ARBs (15.7 vs. 10.5%; P< 0.001) (Table 1).
Hemodynamics and treatment strategy
By definition, all patients underwent coronary angio-
graphy. There was no significant difference noted in
the use of vasopressors and intra-aortic balloon pump
(IABP) between both groups (women vs. men: 6.2 vs.
7.3%, P¼ 0.351; 9.7 vs. 10.5%, P¼ 0.55, respectively).
Resuscitation was similarly prevalent among both groups
(women vs. men: 6.7 vs. 8.7%; P¼ 0.12). However, more
men than women were intubated at the time of admission
(8.5 vs. 5.7%; P¼ 0.025). LVEF was similar in both
groups (women vs. men: 52.0 11.9 vs. 52.9 11.4%;
P¼ 0.22). SBP and heart rate (HR) were significantly
higher in women as compared with men (132.0 27.8 vs.
124.6 26.3mmHg, P< 0.001; 75.7 15.0 vs. 73.9
15.1 b.p.m., P¼ 0.002).
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Table 1 Baseline characteristics (nU2612 patients)
Total (N¼2612) Men (n¼2011) Women (n¼601) P
Age 63.8212.50 62.4012.25 68.5712.19 <0.001
BMI 27.368.55 27.529.12 26.786.00 0.001
ACS type
STEMI 1371/2612 (52.5%) 1057/2011 (52.6%) 314/601 (52.2%) 0.89
NSTEMI 1011/2612 (38.7%) 777/2011 (38.6%) 234//601 (38.9%)
Unstable angina 230//2612 (8.8%) 177//2011 (8.8%) 53//601 (8.8%)
Cardiovascular risk factors
HTN 1455/2604 (55.9%) 1083/2005 (54.0%) 372/599 (62.1%) <0.001
DM 487/2604 (18.7%) 362/2005 (18.1%) 125/599 (20.9%) 0.12
Hyperlipidemia 1027/2604 (39.4%) 806/2005 (40.2%) 221/599 (36.9%) 0.15
Current smoker 1086/2604 (41.7%) 898/2005 (44.8%) 188/599 (31.4%) <0.001
Obesity 550/2604 (21.1%) 416/2005 (20.7%) 134/599 (22.4%) 0.39
FH 678/2603 (26.0%) 514/2005 (25.6%) 164/598 (27.4%) 0.38
Medication on admission
Aspirin 983//2596 (37.9%) 750//2000 (37.5%) 233//596 (39.1%) 0.48
Clopidogrel 371//2597 (14.3%) 280//2001 (14.0%) 91//596 (15.3%) 0.44
Statin 812//2596 (31.3%) 637//2001 (31.8%) 175//595 (29.4%) 0.26
Beta-blocker 746//2597 (28.7%) 570//2001 (28.5%) 176//596 (29.5%) 0.62
ACE-inhibitor 455//2597 (17.5%) 357//2001 (17.8%) 98//596 (16.4%) 0.43
Diuretics 496//2597 (19.1%) 354//2001 (17.7%) 142//596 (23.8%) 0.001
ARBS 376//2596 (14.5%) 266//2001 (13.3%) 110//595(18.5%) 0.002
CCBs 245//2597 (9.4%) 174//2001 (8.7%) 71//596 (11.9%) 0.018
Warfarin 92//2597 (3.5%) 69//2001 (3.4%) 23//596 (3.9%) 0.63
Medication at discharge
Aspirin 2470//2607 (94.7%) 1907//2007 (95.0%) 563/601 (93.8%) 0.25
Clopidogrel 1940//2606 (74.4%) 1453//2007 (72.4%) 487//599 (81.3%) <0.001
Statin 2306///2607 (88.5%) 1795//2007 (89.4%) 511//600 (85.2%) 0.004
Beta-blocker 1514//2607 (58.1%) 1170//2007 (58.3%) 344//600 (57.3%) 0.68
ACE-inhibitor 1685//2607 (64.6%) 1344//2007 (67.0%) 341//600 (56.8%) <0.001
Diuretics 561//2605 (21.5%) 402//2006 (20.0%) 159//599 (26.5%) 0.001
ARBS 304//2604 (11.7%) 210//2005 (10.5%) 94//599 (15.7%) <0.001
CCBs 181/2606 (6.9%) 142/2007 (7.1%) 39/599 (6.5%) 0.63
Warfarin 79/2606 (3.0%) 57/2007 (2.8%) 22/599 (3.7%) 0.30
ACE-inhibitor, angiotensin-converting enzyme inhibitor; ARBs, angiotensin receptor blockers; CCBs, calcium channel blockers; DM, diabetes mellitus; FH, family history;
HTN, hypertension; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction.
Table 2 Baseline characteristics, (part 2)
Total Men Women P
Medication acutely
Vasopressors 183/2611 (7.0%) 146/2010 (7.3%) 37/601 (6.2%) 0.35
GPIIb/IIIa 602/2606 (23.1%) 481/2005 (24.0%) 121/601 (20.1%) 0.049
Emergency procedures
Intubation 204/2612 (7.8%) 170/2011 (8.5%) 34/601 (5.7%) 0.025
Resuscitation 214/2612 (8.2%) 174/2011 (8.7%) 40/601 (6.7%) 0.12
IABP 269/2612 (10.3%) 211/2011 (10.5%) 58/601 (9.7%) 0.55
Unstable 234/2611 (9.0%) 184/2010 (9.2%) 50/601 (8.3%) 0.53
Vital signs on admission (meanSD)
HR (b.p.m.) 74.3115.11 73.8815.12 75.7315.03 0.002
SBP (mmHg) 126.3126.79 124.6126.26 131.9927.80 <0.001
DBP (mmHg) 70.0115.19 70.3515.04 68.0015.62 0.13
Hemodynamic parameters (meanSD)
LVEDP (mmHg) 19.748.30 19.648.38 20.108.02 0.23
LVEF (%) 52.6611.51 52.8611.40 51.9611.89 0.22
Location of the lesion
LM 46/2611 (1.8%) 36/2011 (1.8%) 10/601 (1.7%) 0.84
LAD 1179/2611 (45.2%) 908/2011 (45.2%) 271/601 (45.1%) 0.98
LCX 506/2611 (19.4%) 394/2011 (19.6%) 112/601 (18.6%) 0.60
RCA 823/2611 (31.5%) 626/2011 (31.1%) 197/601 (32.8%) 0.45
Graft 56/2611 (2.1%) 45/2011 (2.2%) 11/601 (1.8%) 0.55
Coronary angiography findings
Single-vessel disease 1069/2591 (41.3%) 799/2011 (39.7%) 270/601 (44.9%) 0.023
Multivessel disease 1522/2591 (58.7%) 1195/2011 (59.4%) 327/601 (54.4%) 0.029
Kind of intervention
PCI 2410/2612 (92.2%) 1858/2011 (92.4%) 552/601 (91.8%) 0.66
CABG 96/2612 (3.7%) 79/2011 (3.9%) 17/601 (2.8%) 0.21
No intervention 106/2612 (4.1%) 74/2011 (3.7%) 32/601 (5.3%) 0.07
CABG, coronary artery bypass graft; GPIIb/IIIa, glycoprotein IIb/IIIa inhibitor; HR, heart rate; IABP, intra-aortic balloon pump; LAD, left anterior descending artery; LCX, left
circumflex artery; LM, left main; LVEDP, left ventricular end-diastolic pressure; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; RCA, right
contrary artery.
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Culprit lesions were assessed in the two groups (Table 2).
SVD was less common in men than in women (39.7 vs.
44.9%; P¼ 0.023); conversely, MVD was more prevalent
in men as compared with women (59.4 vs. 54.4%;
P¼ 0.029). Lastly, glycoprotein IIb/IIIa antagonists
(GPIIb/IIIa) were administered more frequently among
men as compared with women (24.0 vs. 20.1%; P¼ 0.049).
Laboratory values
Troponin-T values on admission were higher in women
than in men (1.33 4.64 vs. 1.19 3.04mg/l; P¼ 0.002).
However, no difference in peak values of troponin-T was
noted during hospitalization (women vs. men: 4.15 7.09
vs. 4.17 6.85mg/l; P¼ 0.62). N-terminal of the pro-
hormone brain natriuretic peptide (NT-proBNP) on
admission and peak values were significantly higher in
women as compared with men (3456.2 7286.7 vs.
1665.6 4800.6 ng/l, P< 0.001; 5781.9 9880.4 vs.
2986.5 6722.5 ng/l, P< 0.001, respectively). Also,
high-density lipoprotein (HDL) cholesterol levels were
significantly higher in women than inmen (1.29 0.41 vs.
1.08 0.33mmol/l; P< 0.001). However, low-density
lipoprotein (LDL) levels were similar in both groups
(3.16 1.18 vs. 3.11 1.09mmol/l; P¼ 0.80). C-reactive
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Table 3 Laboratory values
Total Men Women P
Cholesterol (mmol/l) 4.81 (1.22) 4.77 (1.20) 4.95 (1.26) 0.018
HDL (mmol/l) 1.13 (.036) 1.08 (.33) 1.29 (0.41) <0.001
LDL (mmol/l) 3.12 (1.11) 3.11 (1.09) 3.16 (1.18) 0.80
TG (mmol/l) 1.39 (1.01) 1.44 (1.06) 1.20 (0.75) <0.001
CRP on ad (mg/l) 15.89 (36.94) 15.33 (36.67) 17.80 (37.79) <0.001
CRP max (mg/l) 58.32 (90.15) 59.41 (91.38) 54.67 (85.84) 0.76
WBC on ad (g/l) 10.96 (4.35) 11.05 (4.35) 10.65 (4.26) 0.043
WBC max (g/l) 12.53 (5.43) 12.65 (5.51) 12.10 (5.13) 0.018
CK on ad (U/l) 600.84 (1150.62) 615.99 (1182.02) 546.06 (1032.15) 0.08
CK max (U/l) 1619.57 (2322.06) 1699.82 (2449.35) 1343.51 (1791.97) 0.008
CK-MB on ad (U/l) 80.94 (131.25) 79.30 (126.67) 86.68 (146.07) 0.020
CK-MB max (U/l) 167.14 (219.36) 166.79 (223.91) 168.32 (203.21) 0.61
Myoglobin on ad (mg/l) 525.66 (1116.11) 542.40 (1152.86) 467.99 (977.86) 0.56
Myoglobin max (mg/l) 958.05 (2145.17) 1020.99 (2233.95) 863.22 (1808.67) 0.08
Troponin-T on ad (mg/l) 1.22 (3.46) 1.19 (3.04) 1.33 (4.64) 0.002
Troponin-T max (mg/l) 4.17 (6.90) 4.17 (6.85) 4.15 (7.09) 0.62
NT-proBNP on ad (ng/l) 2068.88 (5509.27) 1665.55 (4800.64) 3456.19 (7286.74) <0.001
NT-proBNP max (ng/l) 3617.90 (7639.52) 2986.53 (6722.54) 5781.90 (9880.35) <0.001
CK, creatine kinase; CRP, C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NT-proBNP, N-terminal of the prohormone brain natriuretic
peptide; TG, triglyceride; WBC, white blood count.
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protein (CRP) levels on admission were significantly
higher among women than among men (17.8 37.8 vs.
15.3 36.7mg/l; P< 0.001); however, peak CRP levels
did not differ (54.7 85.8 vs. 59.4 91.4mg/l; P¼ 0.76).
We did not find any differences between female and
male patients either in BNP levels (women vs. men:
1811.1 3932.6 vs. 1553.9 5801.7 ng/l; P¼ 0.16) or in
CRP levels on admission (women vs. men: 9.68 28.1 vs.
7.03 17.0 ng/l; P¼ 0.72). Laboratory values for both
groups are shown in Table 3.
Follow-up data
The overall mortality rate was 4.86% and virtually similar
in women andmen (4.83 vs. 4.87%; P¼ 0.96). There were
no significant differences for cardiovascular compli-
cations such as cardiogenic shock, tamponade, ventricle
septum defect, stent thrombosis, myocardial infarction,
repeat percutaneous coronary intervention (PCI), CABG
and cerebrovascular accidents (Fig. 2).
The Kaplan–Meier survival curve for 30 days’ follow-up,
including the combined endpoint of in-hospital death,
nonfatal myocardial infarction, revascularization, CABG,
stent thrombosis, as well as stroke, revealed no difference
between men and women (P¼ 0.98) (Fig. 3).
Using univariate analysis, the following parameters
emerged as predictors of MACCEs in female patients
(Table 4): heart rate on admission, SBP on admission,
maximal troponin, maximal creatine kinase (CK),
maximal NT-proBNP and maximal CRP. Predictors of
in-hospital death were (Table 5): heart rate, SBP on
admission, maximal troponin, maximal CK, maximal
NT-proBNP, maximal CRP and GPIIb/IIIa use. After
adjustment for parameters entered into the multivariate
model only maximal CK (OR 1.0, 95% CI 1.00–1.00,
P¼ 0.0056) and peak levels of CRP (OR 1.00, 95% CI
1.00–1.01, P¼ 0.0010) remained significant independent
predictors for MACCEs (Table 4). Strong independent
predictors for in-hospital death were SBP (OR 0.96, 95%
CI 0.93–0.98, P¼ 0.0005), maximal CRP (OR 1.01, 95%
CI 1.00–1.01, P¼ 0.044) and GPIIb/IIIa use (OR 0.07,
95% CI 0.00–0.81, P¼ 0.0295) (Fig. 4, Table 5).
Discussion
While for nearly two decades, disparities in the manage-
ment and prevention of cardiovascular disease in women
have been acknowledged,15 very few RCTs adequately
incorporated women.16,17 Current guidelines are there-
fore often based primarily on information collected in
men. This is of particular clinical importance as the
clinical outcomes are far less favorable in women when
compared with their male counterparts.18,19 There is
evidence that gender-related differences in the mani-
festation and presentation of cardiovascular disease
exist. For instance, in ACS, women are less likely to
present with classical angina symptoms.20 In fact, most
often, women with myocardial infarction will have acute
respiratory and abdominal complaints as opposed to
chest pain. Similarly, in stable CAD, diagnostic tests
such as treadmill or bicycle exercise test are less sensitive
and specific in women.21 Therefore, it is plausible that
ACS is both underdiagnosed and/or misdiagnosed in
women, which in turn may explain the poor in-hospital
outcomes, particularly in younger women.22 Further-
more, medical and invasive treatment has been reported
to be inferior in women.23,24 Moreover, 30-day mortality
in ACS has been found to be higher in women. In
contrast, different studies demonstrated more favorable
cardiac remodeling in elderly women and a better survi-
val after myocardial infarction as compared with men.
This has been elucidated by the protective estrogen
regimen, different beta-adrenergic stimulation, renin–
angiotensin system and greater resistance to apoptosis in
women.25
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revealing no significant differences.
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Despite similar outcome measures, our results confirm
the higher prevalence of MVD in male patients as com-
pared with women presenting with ACS. The discre-
pancy in CAD extent between men and women has been
already reported and is explained by the protective
influence of estrogen regimen.25 Although more women
tend to have low-risk angiographic lesions, they continue
to suffer more postintervention complications.3,22,26
Interestingly, previously reported data from Switzerland
suggest that in-hospital mortality in STEMI patients
might now be equivalent between the sexes.27 Similarly,
our single-center registry from 2007 to 2012 confirms that
in-hospital death rate today is similar between men and
women. This may be indicative of a closing gap in short-
term outcomes possibly linked to the heightened aware-
ness of cardiovascular disease in women. In addition,
complications were equivalent amongst men and women.
Also, treatment differences in the use of IABP and
resuscitation were the same between the two groups,
further highlighting a change in recent clinical treatment
approach in women presenting with ACS.
Of note, acute treatment with GPIIb/IIIa inhibitors was
substantially different between the sexes. There is evi-
dence that GPIIb/IIIa inhibitors positively influence
30-day mortality and reduce target vessel revasculari-
zation (TVR). However, we did not observe a better
outcome with GPIIb/IIIa use in our male population
regarding TVR and in-hospital mortality rates, although
according to guidelines, male patients were significantly
more likely to be treated with GPIIb/IIIa inhibitors.
Interestingly, in women, GPIIb/IIIa administration was
a strong independent predictor of in-hospital death, but
not MACCEs. Given that our observations were based on
the current registry, further RCTs are needed to probe
this hypothesis.
It is noteworthy that certain distinct characteristics were
observed in the two groups. At the time of presentation,
women were older and more likely to have hypertension,
whereas men were more likely to be smokers. Interest-
ingly, laboratory values on admission including troponin
were significantly lower in female patients, whereas
maximum troponin levels were similar. This is in line
with previous studies. Such findings have raised concerns
regarding the need for gender-specific cut-off levels,
since thus far investigations have focused primarily on
laboratory cut-off values primarily derived from male
populations.28 Plaque disturbances differ amongst men
and women, which might at least in part explain differ-
ences in biomarker levels. Indeed in men, plaque rup-
tures appear more common, leading more often to
complete coronary occlusion, whereas in women, plaque
erosions are more often the culprit. Plaque rupture may
serves as a strong impulse for recurrent thrombus embo-
lization with high troponin release as compared with
women.29
The fact that NT-proBNP was higher at baseline and
peaked in women might be related to their higher age.
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Kaplan–Meier survival curve for short-term follow-up (30 days) in
patients with acute coronary syndromes in women compared with men
demonstrating no siginficant difference (P¼0.98).
Table 4 Predictor of events on nominal logistic regression models (in female study population)
MACCE (n¼47)
Univariate OR (95% CI) P value Multivariate OR (95% CI) P value
Age 1.00 (0.98, 1.04) 0.32 1.02 (0.98, 1.0) 0.33
Heart rate 1.02 (0.99, 1.04) 0.06 0.98 (0.95, 1.01) 0.21
SBP on admission 0.96 (0.95, 0.98) <0.0001 0.97 (0.95, 0.99) 0.0019
Troponin max 1.08 (1.05, 1.12) <0.0001 1.01 (0.94, 1.08) 0.69
CK max 1.00 (1.00, 1.01) <0.0001 1.00 (1.00, 1.00) 0.0056
NT-proBNP max 1.00 (1.00, 1.01) <0.0001 1.00 (0.99, 1.00) 0.46
CRP max 1.007 (1.006, 1.008) <0.0001 1.00 (1.00, 1.01) 0.001
Aspirin on admission 1.54 (0.83, 2.84) 0.17 2.85 (0.89, 9.52) 0.07
Statins on admission 1.41 (0.73, 2.65) 0.30 0.90 (0.27, 2.93) 0.87
GPIIb/IIIa 0.80 (0.34, 1.68) 0.57 0.45 (0.11, 1.52) 0.21
CI, confidence interval; CK, creatine kinase; CRP, C-reactive protein; GPIIb/IIIa, glyocoprotein IIb/IIIa inhibitor; MACCE, major adverse cardiac and cerebrovascular events;
NT-proBNP, N-terminal of the prohormone brain natriuretic peptide; OR, odds ratio.
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Indeed, NT-proBNP levels increase with age.30 As
LVEF was similar in both groups, left ventricular
dysfunction is unlikely to contribute to these findings.
However, as long as the cut-off points for BNP and
NT-proBNP are still under debate, the meaning of this
finding remains an interesting observation with unclear
clinical relevance.28
Furthermore, CRP levels at presentation were higher in
female ACS patients, a finding also made by others.31
This has been related to a more pronounced systemic
inflammatory activation in female ACS patients com-
pared with men.28 However, recent investigations by
other groups have failed to show an increase in other
inflammation markers such as myeloperoxidase, CD-40
ligands or interleukin (IL)-10 in women.32–34 Neverthe-
less, peak CRP levels emerged as an independent pre-
dictor for MACCEs and death in both men and women.
Indeed, we previously found that NSTEMI, which pre-
sent more commonly as heralded infarction, exhibit
higher CRP values as they have already ongoing inflam-
mation prior to presentation.35
Furthermore, upon admission, certain medications such
as CCBs, diuretics and ARBs were administered more
frequently in women compared with men, most likely
due to the higher prevalence of hypertension. Discharge
medications also differed significantly, such that clopido-
grel, diuretics and ARBs were administered significantly
more in women. Conversely, statins, ACE-inhibitors and
the new antiplatelet agents such as tigacrelor and prasu-
grel were more frequently administered in men at dis-
charge.
In most studies published so far, women suffered a worse
outcome after ACS. Amongst proposed factors are hor-
monal influences, the presence of more comorbidities
and even psychosocial or economic differences between
the two groups.
Moreover, drug response varies between the male and
female gender, which can further add a layer of complex-
ity in interpreting the outcomes. In contrast to previous
registries, however, we remarkably found a similar short-
term outcome between male and female patients with
ACS. This strongly suggests that with early reperfusion
using PCI and the use of modern adjunct pharmacother-
apy, the gender gap can be closed in high-volume tertiary
centers of high quality.
Small gender-specific differences, however, continue to
exist, and medical management of female patients can
improve further. For instance, our study revealed that
treatment with statins as a part of the discharge medi-
cation regimen was slightly under-represented in women.
Whereas the short-term outcomes are not affected, this
might influence the long-term outcomes.
Thus, in summary, our study highlights that short-term
outcome is similar between male and female patients
presenting with ACS; therefore, the gender gap is closing.
This improvement in women may be related to the
finding that women andmen received equally emergency
treatment and PCI as our data show; however, gender
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Table 5 Predictor of events on nominal logistic regression models (in female study population)
All-cause death (n¼29)
Univariate OR (95% CI) P value Multivariate OR (95% CI) P value
Age 1.01 (0.98, 1.04) 0.59 1.02 (0.95, 1.08) 0.55
Heart rate 1.03 (1.01, 1.06) 0.0099 0.99 (0.96, 1.03) 0.80
SBP on admission 0.95 (0.93, 0.96) <0.0001 0.96 (0.93, 0.98) 0.0005
Troponin max 1.09 (1.05, 1.12) <0.0001 1.03 (0.95, 1.11) 0.47
CK max 1.00 (1.00, 1.00) <0.0001 1.00 (0.99, 1.00) 0.13
NT-proBNP max 1.00 (1.00, 1.00) <0.0001 1.00 (0.99, 1.00) 0.22
CRP max 1.01 (1.00, 1.01) <0.0001 1.01 (1.00, 1.01) 0.044
Aspirin on admission 0.77 (0.32, 1.70) 0.53 1.39 (0.27, 6.47) 0.68
Statins on admission 0.88 (0.34, 2.04) 0.77 0.51 (0.07, 3.14) 0.48
GPIIb/IIIa 0.28 (0.05, 0.96) 0.0415 0.07 (0.00, 0.81) 0.0295
CI, confidence interval; CK, creatine kinase; CRP, C-reactive protein; GPIIb/IIIa, glyocoprotein IIb/IIIa inhibitor; MACCE, major adverse cardiac and cerebrovascular events;
NT-proBNP, N-terminal of the prohormone brain natriuretic peptide; OR, odds ratio.
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disparities in baseline characteristics exist and medical
treatment is still different, and heightened awareness of
this issue is a prerequisite among clinicians.
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